FindTrial
Sign In

Cohort Study to Explore the Therapeutic Effect of Lenvatinib on Differentiated Thyroid Cancer

Cohort Study to Explore the Therapeutic Effect of Lenvatinib on Differentiated Thyroid Cancer - COLLECT (Cohort Study of Lenvatinib (LEnvima) in Differentiated Cancer of Thyroid)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000022243
Enrollment
300
Registered
2016-05-26
Start date
2016-08-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Differentiated Thyroid Cancer

Interventions

None listed

Sponsors

Public Health Research Foundation
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Patient with curatively unresectable, RAI-refractory and progressive DTC who is determined suitable for treatment with lenvatinib 2)Patient who began treatment with lenvatinib after this study passed review by the facility's review committee 3)Patient who has given consent to participate in the study

Exclusion criteria

Exclusion criteria: 1)Patient deemed unsuitable to participate in this study by the attending physician

Design outcomes

Primary

MeasureTime frame
Overall Survival—

Secondary

MeasureTime frame
1)Time to Treatment Failure 2)Time to Failure of Strategy 3)Progression-Free Survival with clinical Progressive Disease 4)Response Rate 5)QOL survey 6)Safety 7)Patient Reports—

Countries

Japan

Contacts

Public ContactAkira Yamao

Public Health Research Foundation Comprehensive Support Project for Oncology Research (CSPOR)

cspor-dtc@csp.or.jp03-5287-2636

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026